Offline smartphone AI fundus screening detects diabetic retinopathy, glaucoma, and macular degeneration in one capture, delivering high accuracy for low-resource eye care.
News|Videos|November 14, 2021
Influence of universal face masks on endophthalmitis risk post-anti-VEGF injections
Author(s)Sheryl Stevenson, Alex Delaney-Gesing
Sunir J. Garg, MD, speaks on the influence of COVID-19 universal face masking on the risk of endophthalmitis following intravitreal anti-VEGF injections.
Advertisement
Ophthalmology Times' Sheryl Stevenson speaks with Sunir J. Garg, MD, co-director of retina research at the Wills Eye Hospital in Baltimore, Maryland, on the highlights of his presentation at the 2021 annual American Academy of Ophthalmology (AAO) meeting regarding the impact of
Advertisement
Related to this article
Sura-vec is a 1-time investigational gene therapy designed to deliver sustained treatment in wet AMD, diabetic retinopathy and other chronic retinal conditions.
Ultra-widefield imaging reveals early retinal risk in pediatric patients.
Study finds ChatGPT-5 overpredicts success after macular hole surgery—beating specialists on paper but missing failures.
The newly formed biotech will use the financing to push MMT-205, a bispecific antibody that directly activates Tie2 while inhibiting VEGF, toward IND-enabling studies, with first-in-human trials slated for 2027.
Atsena reported that, since enrollment opened in May 2026, it has already accrued approximately 10% of the pivotal cohort and expects the pace to accelerate as additional sites across North America and Europe are activated.
The 2-day program at the Gaylord Opryland Resort will bring together established and emerging eye care leaders for sessions on leadership development, artificial intelligence, inclusion, and career growth.
Belite Bio has completed its rolling NDA submission to the FDA for tinlarebant, a potential first approved treatment for Stargardt disease type 1.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
AAO 2026: BRUNELLO 1-year results for remigromig in DME
2
AAO 2026: MCO-010 sustains vision gains in RP through 4 years
3
AAO 2026: Optogenetic gene therapy heads to phase 2 trial in geographic atrophy
4
AAO 2026: DAYBREAK shows tarcocimab and tabirafusp-ted noninferior to aflibercept in wet AMD
5